Immune landscape of pancreatic cancer development and drug resistance.
Immune landscape of pancreatic cancer development and drug resistance explores the advances in immune-based therapies aimed at harnessing the power of the immune system against pancreatic cancer and rewiring tumor microenvironments to eradicate pancreatic cells.
Guardat en:
| Format: | eBook |
|---|---|
| Idioma: | anglès |
| Publicat: |
[S.l.] :
Academic Press,
2024.
|
| Col·lecció: | Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy ;
v. 5 |
| Matèries: | |
| Accés en línia: | ScienceDirect |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
MARC
| LEADER | 00000cam a2200000 a 4500 | ||
|---|---|---|---|
| 001 | on1438916126 | ||
| 003 | OCoLC | ||
| 005 | 20260915095215.0 | ||
| 006 | m o d | ||
| 007 | cr |n||||||||| | ||
| 008 | 240612s2024 xx o 000 0 eng d | ||
| 040 | |a YDX |b eng |c YDX |d OPELS |d OCLCO |d UKAHL |d UKKRT |d OCLCL |d SFB | ||
| 020 | |a 9780443235221 |q (electronic bk.) | ||
| 020 | |a 0443235228 |q (electronic bk.) | ||
| 020 | |z 9780443235238 | ||
| 020 | |z 0443235236 | ||
| 035 | |a (OCoLC)1438916126 | ||
| 050 | 4 | |a RC280.P25 | |
| 082 | 0 | 4 | |a 616.99/437 |2 23/eng/20240625 |1 https://id.oclc.org/worldcat/ddc/E3Mh4wXqhKwpWBgwBcDq3cdjgp |
| 245 | 0 | 0 | |a Immune landscape of pancreatic cancer development and drug resistance. |
| 260 | |a [S.l.] : |b Academic Press, |c 2024. | ||
| 300 | |a 1 online resource | ||
| 490 | 0 | |a Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy ; |v v. 5 | |
| 505 | 8 | |a Napabucasin for metastatic PDAC -- Atezolizumab and cabozantinib for metastatic PDAC -- Dendritic cell vaccine in PDAC -- Conclusion -- References -- Chapter 4: Targeting macrophages for pancreatic cancer therapy -- Introduction -- How do TAMs originate? -- Role of TAMs in PDAC inflammation -- Angiogenesis -- Metastasis -- Immunity escape -- Chemotherapy resistance -- TAMs polarization -- Colony-stimulating factors, cytokines, and other molecules -- Inflammation related to TLRs -- Metabolic factors -- Exosomes -- Therapeutic potential of TAMs -- Redirection of TAMs -- Decreasing the amount of TAMs in ECM -- Conclusions and future prospects -- Funding -- References -- Chapter 5: Targeting cancer-associated fibroblasts in pancreatic ductal adenocarcinoma -- Introduction -- Tumor microenvironment -- Cancer-associated fibroblasts -- Quiescent cancer-associated fibroblasts -- Activated cancer-associated fibroblasts -- PDAC-associated fibroblast populations and their paracrine signaling -- Therapeutic targets of cancer-associated fibroblasts -- Targeting approaches for cancer-associated fibroblasts -- Direct approach -- Targeting the surface markers -- Targeting the signaling pathways between CAFs and TME -- Modifying CAFs from ``activeþþ to ``quiescentþþ stage -- Targeting CAF-derived ECM proteins -- Indirect approaches -- CAF causing therapeutic resistance -- Conclusion -- References -- Chapter 6: Targeting short-lived immunosuppressive myeloid cells for PDAC therapy -- Introduction -- Immune response in tumor cells -- Overview of types of myeloid cells found in the tumor microenvironment -- Myeloid-derived suppressor cells -- Methods of immunosuppression by MDSCs -- Tumor-associated macrophages -- Dendritic cells -- Importance of targeting myeloid immunosuppression -- Different examples of short-lived myeloid immunosuppression in PDAC. | |
| 505 | 8 | |a Vaccines directed against the VEGF receptor -- Kinesin family member 20A protein -- Survivin -- Mesothelin -- Other common cancer vaccines -- Local ablation along with immunotherapy -- Irreversible electroporation with immunotherapy -- Stereotactic ablative body radiotherapy with immunotherapy -- Summary -- Funding -- References -- Chapter 10: Precision medicine for PDAC immunotherapy -- Introduction -- Overview of pancreatic ductal adenocarcinoma -- Defining precision medicine -- Call for targeted therapy in the treatment of PDAC -- Types of treatments of PDAC using precision medicine -- Precision medicine targets of chemotherapy -- Precision medicine targets of immunotherapy -- Targeting immune checkpoint inhibitors in tumors with microsatellite instability (MSI)/defective DNA mismatch repair (dMMR) -- Chimeric antigen receptor (CAR) T-cell therapy -- Targeting inhibition of connective tissue growth factor (CTGF) -- Precision medicine combining both chemotherapy and immunotherapy -- Vaccine therapy -- Targeting CD40 in combination with chemotherapy -- Autophagy and hydroxychloroquine in combination with chemotherapy -- Conclusion -- References -- Chapter 11: Application of artificial intelligence and machine learning in pancreatic cancer immunotherapy -- Introduction -- Challenges in the field -- Pancreatic cancer -- Immunotherapy -- Applications of AI/ML in pancreatic cancer immunotherapy -- Early diagnosis -- Medical imaging -- Endoscopic ultrasound (EUS) -- Computed tomography (CT) -- Magnetic resonance imaging (MRI) -- Precision medicine and predictive modeling -- Immunotherapy -- Challenges and future perspectives -- References -- Chapter 12: Enigmatic role of T cells in pancreatic ductal adenocarcinoma: An introspective study -- Introduction -- Tumor microenvironment of PDAC -- Role of T-cells in the progression and pathogenesis of PDAC. | |
| 505 | 8 | |a T-cell phenotypes playing a crucial role in PDAC -- Mechanisms behind T-cell exhaustion in PDAC -- Status of T-cell-based immunotherapy in PDAC -- Conclusion -- References -- Chapter 13: Delivery strategies of immunotherapies in the treatment of pancreatic cancer -- Introduction -- Cancer immunotherapy -- Passive immunotherapy -- Monoclonal antibodies -- Cytokine therapies -- Adoptive cell transfer therapy -- Active immunotherapy -- Peptide vaccines -- Dendritic cells (DCs) -- Whole-cell vaccines -- Immune checkpoint inhibitors (ICIs) -- Oncolytic viruses -- Delivery strategies for immunotherapy -- Nanoparticles -- Extracellular vesicles -- Implantable scaffolds -- Injectable scaffolds -- Cell-based delivery systems -- Conclusion -- Acknowledgment -- References -- Chapter 14: Current clinical trials in pancreatic ductal adenocarcinoma immunotherapy -- Introduction -- PDAC current therapeutic options -- Common chemotherapy regimens -- PDAC radiation therapy -- Limitations: Limitations of current therapeutic options -- Gemcitabine resistance -- Immunotherapy in cancer -- Immune checkpoint inhibitors -- Application of immunotherapy for PDAC -- Clinical trials -- Conclusion -- References -- Chapter 15: Managing adverse effects of novel immunotherapy in pancreatic cancer -- Introduction -- Immunotherapy -- Immune-checkpoint inhibitors -- Side effects and management of immunotherapy -- Cutaneous irAEs -- GI irAEs -- Liver irAEs -- Pancreas irAEs -- Pulmonary irAEs -- Endocrine irAEs -- Neurological irAEs -- Cardiac irAEs -- Conclusions and future perspectives -- Authors contribution -- References -- Chapter 16: Cathepsin B: Structure-function, metastatic role, and prognostic value in pancreatic carcinoma -- Introduction -- Structure-functional properties of cathepsin B and its metastatic role in pancreatic carcinoma -- Structure of cathepsin B. | |
| 520 | |a Immune landscape of pancreatic cancer development and drug resistance explores the advances in immune-based therapies aimed at harnessing the power of the immune system against pancreatic cancer and rewiring tumor microenvironments to eradicate pancreatic cells. | ||
| 650 | 0 | |a Pancreas |x Cancer |x Immunological aspects. | |
| 650 | 6 | |a Pancréas |0 (CaQQLa)201-0288909 |x Cancer |0 (CaQQLa)201-0288909 |x Immunologie. |0 (CaQQLa)201-0380076 | |
| 776 | 0 | 8 | |c Original |z 0443235236 |z 9780443235238 |w (OCoLC)1391434844 |
| 856 | 4 | 0 | |3 ScienceDirect |u https://www.sciencedirect.com/science/book/9780443235238 |